Reported results
- Net loss for the third quarter of 2026 was $3.6 million, compared to $3.5 million for the three months ended September 30, 2025.
- Net loss per share for the third quarter of 2026 was $0.21, compared to $0.79 for the three months ended September 30, 2025.
- Research and development expenses for the third quarter of 2026 were $0.2 million, compared to $0.6 million for the three months ended September 30, 2025.
- General and administrative expenses for the third quarter of 2026 were $2.6 million, compared to $3.0 million for the same period in 2025.
- Financing costs related to the Lincoln Park equity line of credit for the third quarter of 2026 were $0.8 million.
Guidance
- The Company’s existing cash and cash equivalents are expected to fund its projected operating expense requirements for less than 12 months from the date the financial statements were available to be issued.
- An investigator-initiated trial in China evaluating TPST-4003 in approximately 10 patients with myasthenia gravis or multiple sclerosis is expected to begin in the fourth quarter of 2026.
Notes
The Company stated there is substantial doubt about its ability to continue as a going concern.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.
